Keen Vision Acquisition Corp

Keen Vision Acquisition Corp (KVAC) Stock Analysis

$11.510

-1.511 (-13.13%)At close

Loading chart…
High
12.000
Open
11.925
VWAP
11.67
Vol
35.17K
Mkt Cap
205.09M
Low
11.510
Amount
410.54K
EV/EBITDA, TTM
0.00

Keen Vision Acquisition Corporation is a blank check company. The Company is formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses. The Company is an early-stage company and an emerging growth company. The Company has neither engaged in any operations nor generated any revenues.

www.kv-ac.com

Valuation Metrics

The current forward P/E ratio for Keen Vision Acquisition Corp (KVAC) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Fair
5Y Average P/S
0.11
Current P/S
0.00
Overvalued
1.22
Undervalued
-1.01

Alphio AI Price Scenarios for KVAC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%KVAC

$14.38

Scenario price

B

Base

Base · 50%KVAC

$13.67

Scenario price

B

Bear

Bear · 25%KVAC

$12.96

Scenario price

Whales holding KVAC

W

W. R. Berkley Corporation

+ HoldingKVAC

-0.55%

3M Return

Events Timeline

2025-07-15 (ET)

08:04:56

Medera, University of Kansas report first patient treated in gene therapy trial

2025-06-24 (ET)

08:10:28

Medera, Novoheart announce collaboration with scientists at University of CA

2025-06-13 (ET)

08:06:33

Medera, Novoheart present breakthroughs in human mini-heart platforms, therapy

2025-05-19 (ET)

08:15:18

Medera showcases interim data from first-in-human gene therapy trial

2025-04-01 (ET)

08:05:55

Medera presents updated results from gene therapy trial for heart failure

News

KVAC FAQ — answered by Alphio AI

Keen Vision Acquisition Corporation is a blank check company. The Company is formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses. The Company is an early-stage company and an emerging growth company. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector (BLANK CHECKS industry).

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started